Could a lower dose of immunotherapy shrink colorectal tumors before surgery?
NCT ID NCT07523763
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether low doses of the immunotherapy drugs nivolumab or pembrolizumab can shrink tumors in people with a specific genetic type of colorectal cancer (MSI/dMMR) before they have surgery. The study involves 30 participants with stage II-III disease who will receive treatment for 6 months. The main goal is to see if the cancer disappears completely or shows a lasting response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab or pembrolizumab (low-dose immunotherapy)
- What this could lead to
- If successful, this could offer a less toxic, pre-surgery treatment option for certain colorectal cancers, potentially avoiding more aggressive therapies.
- What could go wrong
- This is a small, early-phase study with only 30 participants, so results may not apply to everyone. Low doses might be less effective, and side effects from immunotherapy are still possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
N.N. Blokhin NMRCO
Moscow, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Why are more younger adults getting colorectal cancer? a national study digs into the data
- New drug combo aims to boost response in Hard-to-Treat colorectal cancer
- First-in-Class cancer drug targets Hard-to-Treat tumors
- New pill targets Hard-to-Treat cancers with a specific gene mutation
- AI eye on cancer: robot helps spot hidden polyps
- New hope for Hard-to-Treat colorectal cancer? drug combo trial launches